Your browser is no longer supported. Please, upgrade your browser.
Settings
KERX Keryx Biopharmaceuticals, Inc. daily Stock Chart
KERX [NASD]
Keryx Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own0.60% Shs Outstand103.01M Perf Week3.75%
Market Cap540.80M Forward P/E- EPS next Y-0.61 Insider Trans-7.96% Shs Float101.83M Perf Month10.99%
Income-165.10M PEG- EPS next Q-0.25 Inst Own65.60% Short Float21.31% Perf Quarter-12.94%
Sales28.20M P/S19.18 EPS this Y3.30% Inst Trans2.12% Short Ratio15.61 Perf Half Y13.39%
Book/sh0.21 P/B25.00 EPS next Y57.90% ROA-76.00% Target Price7.21 Perf Year44.23%
Cash/sh- P/C- EPS next 5Y- ROE-302.70% 52W Range3.20 - 7.80 Perf YTD-10.41%
Dividend- P/FCF- EPS past 5Y-27.90% ROI-62.00% 52W High-32.69% Beta4.97
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin0.30% 52W Low64.06% ATR0.31
Employees184 Current Ratio8.70 Sales Q/Q50.00% Oper. Margin- RSI (14)49.20 Volatility6.20% 6.53%
OptionableYes Debt/Eq5.75 EPS Q/Q-34.70% Profit Margin- Rel Volume0.96 Prev Close5.02
ShortableYes LT Debt/Eq5.74 EarningsMar 01 BMO Payout- Avg Volume1.39M Price5.25
Recom2.40 SMA201.26% SMA50-5.59% SMA200-5.02% Volume1,339,814 Change4.58%
Jan-11-17Upgrade Citigroup Sell → Neutral
Nov-09-16Upgrade Maxim Group Hold → Buy $7
Aug-02-16Downgrade Stifel Buy → Hold
Aug-02-16Downgrade FBR Capital Outperform → Mkt Perform $16 → $7
Aug-02-16Downgrade Brean Capital Buy → Hold
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-08-16Reiterated Maxim Group Buy $7 → $9
Mar-30-16Reiterated FBR Capital Outperform $10 → $13
Feb-29-16Upgrade FBR Capital Mkt Perform → Outperform $10
Feb-26-16Upgrade Raymond James Mkt Perform → Outperform
Feb-26-16Reiterated Stifel Buy $10 → $9
Feb-26-16Downgrade JP Morgan Overweight → Neutral
Feb-25-16Reiterated Maxim Group Buy $11 → $5
Oct-05-15Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-09-15Initiated Raymond James Mkt Perform
Sep-03-15Initiated Citigroup Sell
Aug-13-15Initiated Morgan Stanley Underweight $3
Aug-11-15Initiated FBR Capital Mkt Perform $10
Aug-10-15Downgrade ROTH Capital Buy → Neutral $11 → $6
Aug-06-15Reiterated Maxim Group Buy $17 → $11
Feb-27-17 08:21AM  Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?
Feb-24-17 05:06PM  Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
Feb-23-17 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Conferences in March 2017 GlobeNewswire
Feb-16-17 09:15AM  Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017 GlobeNewswire -7.97%
Feb-08-17 09:01AM  Keryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on February 22, 2017 GlobeNewswire
Feb-02-17 04:46PM  Here's Why Keryx Biopharmaceuticals Soared as Much as 15.1% Today at Motley Fool +14.64%
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx Accesswire
Jan-23-17 12:02PM  Keryx Biopharmaceuticals, Inc. Value Analysis (NASDAQ:KERX) : January 23, 2017
Jan-20-17 08:31AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : January 20, 2017
Jan-13-17 06:13PM  Keryx Releases Auryxia Data for Iron Deficiency Anemia
Jan-12-17 09:54AM  Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology GlobeNewswire
Jan-11-17 06:24AM  Keryx Biopharma upgraded by Citigroup
Jan-09-17 08:32AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors o
Jan-08-17 06:00PM  Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-17 02:46PM  Robbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Lawsuit Business Wire
Jan-03-17 02:24PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : January 3, 2017
Dec-30-16 08:35AM  Implied Volatility Surging for Keryx (KERX) Stock Options
Dec-24-16 09:51AM  3 Companies Whose Revenue Could Double in 2017 at Motley Fool
Dec-22-16 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgans 35th Annual Healthcare Conference on January 11, 2017 GlobeNewswire
Dec-19-16 11:48AM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 19, 2016
Dec-15-16 02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group at Insider Monkey
Dec-11-16 04:48AM  Do Hedge Funds Love Keryx Biopharmaceuticals Inc (KERX)? at Insider Monkey
Dec-06-16 03:54PM  This Is Why Keryx Biopharmaceuticals Surged 28% in November at Motley Fool
Dec-05-16 12:18PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 5, 2016
Nov-28-16 09:47AM  3 Biotech Investing Tips That Could Earn You Thousands at Motley Fool
Nov-23-16 01:08PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 23, 2016
Nov-21-16 10:15AM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Nov-18-16 10:31AM  Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASNs Kidney Week GlobeNewswire
08:45AM  Keryx (KERX) Stock Up on Positive Phase III Auryxia Data
Nov-17-16 01:04PM  KERYX BIOPHARMACEUTICALS INC Financials
10:31AM  Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) GlobeNewswire
Nov-11-16 03:41PM  Here's Why Keryx Biopharmaceuticals Soared As Much As 13.1% Today at Motley Fool +13.70%
Nov-10-16 08:27AM  Keryx (KERX) Q3 Loss Wider than Expected, Restores Supply
05:40AM  FDA action helps Keryx move past drug supply snafu at bizjournals.com
Nov-09-16 04:45PM  Why Keryx Biopharmaceuticals Stock Jumped Today at Motley Fool +13.36%
04:39PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events
01:31PM  Edited Transcript of KERX earnings conference call or presentation 9-Nov-16 1:00pm GMT
12:57PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 9, 2016
10:58AM  Here's Why Keryx Biopharmaceuticals Fell 18% in October at Motley Fool
10:42AM  Keryx Biopharmaceuticals Announces U.S. FDA Approval of Second Contract Manufacturer for Auryxia® (ferric citrate) GlobeNewswire
09:16AM  Keryx (KERX) Posts Wider-than-Expected Loss in Q3
08:00AM  Keryx Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
07:42AM  Keryx Biopharma reports 3Q loss
07:07AM  Q3 2016 Keryx Biopharmaceuticals Inc Earnings Release - Before Market Open
07:01AM  Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-16 07:53AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : November 8, 2016
Nov-03-16 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentation at Stifels 2016 Healthcare Conference on November 15 GlobeNewswire -5.88%
Nov-01-16 09:15AM  Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2016 Financial Results on Wednesday, November 9, 2016 GlobeNewswire
07:44AM  Keryx (KERX) Q3 Earnings Preview: Stock to Beat Estimates?
Oct-20-16 01:32PM  Here Are Two Dates To Keep An Eye On In Biotech Across The Next Two Weeks at Insider Monkey +5.45%
Oct-19-16 12:35PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : October 19, 2016
Oct-18-16 08:33AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : October 18, 2016
Oct-17-16 05:28PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure -6.84%
Oct-14-16 10:13AM  Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting GlobeNewswire
Oct-12-16 05:35PM  Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday -8.49%
Oct-09-16 08:28AM  What's Behind Keryx Biopharmaceuticals' 28.6% Jump in September? at Motley Fool
Oct-04-16 10:03AM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : October 4, 2016
Oct-01-16 10:06AM  MONDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
Sep-30-16 10:07PM  KERYX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Keryx Biopharmaceuticals Inc. - KERX Business Wire
01:39PM  3-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
12:35PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 - KERX PR Newswire
Sep-28-16 11:50AM  OCTOBER 3 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
11:25AM  October 3rd Deadline in Lawsuit for Investors in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) announced by Shareholders Foundation GlobeNewswire
10:10AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline: October 3, 2016 Accesswire
Sep-27-16 05:04PM  6-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
04:08PM  October 3rd Deadline Alert: GPM Reminds Investors of the Upcoming Deadline in the Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. and Announces Expanded Class Period Business Wire
02:20PM  DEADLINE ALERT: Brower Piven Notifies Shareholders of October 3, 2016 Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact The Firm - KERX GlobeNewswire
11:02AM  DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
10:18AM  KERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff Deadline of October 3, 2016 GlobeNewswire
Sep-23-16 10:42AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
10:05AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 KERX GlobeNewswire
Sep-22-16 01:25PM  UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
01:07PM  Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming October 3rd Deadline in the Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. Business Wire
Sep-21-16 11:30AM  UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline: October 3, 2016 Accesswire
08:30AM  Keryx Biopharmaceuticals to Webcast its Presentation at Ladenburg Thalmanns 2016 Healthcare Conference GlobeNewswire
Sep-20-16 12:13PM  APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
11:38AM  GPM Reminds Investors of the October 3rd Deadline in the Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Business Wire
Sep-19-16 02:11PM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
01:41PM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 Business Wire
01:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline KERX GlobeNewswire
10:09AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline - October 3, 2016 Accesswire
Sep-17-16 09:17AM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
Sep-16-16 10:07PM  KERYX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. - KERX GlobeNewswire
02:15PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
12:20PM  DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Upcoming Deadline Business Wire
11:06AM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : September 16, 2016
10:52AM  KERYX ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline in Class Action GlobeNewswire
Sep-15-16 11:00AM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
09:40AM  KERX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff Deadline of October 3, 2016 Business Wire
Sep-14-16 05:55PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
04:20PM  Robbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Class Action Business Wire
Sep-09-16 10:53AM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire -5.47%
09:56AM  KERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff Deadline of October 3, 2016 PR Newswire
Sep-08-16 02:20PM  INVESTOR ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline in Class Action - KERX PR Newswire
11:42AM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
10:08AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline - October 3, 2016 Accesswire
09:30AM  KERX DEADLINE: Hagens Berman Reminds Investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) of October 3, 2016 Lead Plaintiff Deadline and of Expanded Securities Case Class Period GlobeNewswire
Sep-07-16 06:10PM  Robbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, Inc. And Lead Plaintiff Opportunity PR Newswire +6.90%
08:32AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Madison GregPresident and CEOFeb 09Sale5.471,6118,812233,711Feb 13 04:18 PM
Madison GregPresident and CEOJan 30Sale4.6518,24884,853235,322Jan 31 04:05 PM
Holmes Scott AChief Financial OfficerJan 30Sale4.658,44739,27998,873Jan 31 04:05 PM
Neylan John F.Chief Medical OfficerJan 30Sale4.656,98432,47683,144Jan 31 04:05 PM
Adams BrianGeneral Counsel and SecretaryJan 30Sale4.656,98432,47692,559Jan 31 04:05 PM
Neylan John F.Chief Medical OfficerJan 23Sale5.391,4287,69790,128Jan 25 04:06 PM
Adams BrianVP and General CounselJan 17Sale6.241,2657,89499,543Jan 18 04:05 PM
Adams BrianVP and General CounselJan 05Sale6.167594,675100,808Jan 06 04:06 PM
Madison GregPresident and CEOJan 05Sale6.161,0776,634253,570Jan 06 04:05 PM
Madison GregPresident and CEONov 09Sale4.991,5597,779254,647Nov 14 04:06 PM
Holmes Scott AChief Financial OfficerOct 28Sale4.441,2375,492107,320Oct 31 04:07 PM
Neylan John F.Chief Medical OfficerOct 24Sale4.721,2115,71691,556Oct 25 04:05 PM
Adams BrianVP and General CounselOct 17Sale4.861,1065,375101,567Oct 18 04:05 PM
Adams BrianVP and General CounselOct 05Sale5.386473,481102,673Oct 06 04:05 PM
Madison GregPresident and CEOOct 05Sale5.389174,933256,206Oct 06 04:05 PM
Madison GregPresident and CEOAug 09Sale4.221,6226,845257,123Aug 11 05:44 PM
Madison GregPresident and CEOAug 09Sale4.221,6226,845257,123Aug 11 05:45 PM
Holmes Scott AChief Financial OfficerJul 29Sale7.364,93536,322108,557Aug 02 05:00 PM
Neylan John F.Chief Medical OfficerJul 25Sale7.431,2179,04292,767Jul 27 05:00 PM
Adams BrianVP and General CounselJul 15Sale7.011,0837,592103,320Jul 18 07:10 PM
Madison GregPresident and CEOJul 05Sale6.669366,234258,745Jul 06 04:17 PM
Adams BrianVP and General CounselJul 05Sale6.666604,396104,403Jul 06 04:18 PM
Madison GregPresident and CEOMay 09Sale5.421,87310,152259,681May 10 04:35 PM
Neylan John F.Chief Medical OfficerApr 25Sale5.214,76624,83193,984Apr 27 04:16 PM
Adams BrianVP and General CounselApr 15Sale5.051,0605,353105,063Apr 18 08:25 PM
Madison GregPresident and CEOApr 05Sale4.501,0784,851261,554Apr 07 05:01 PM
Adams BrianVP and General CounselApr 05Sale4.507593,416106,123Apr 07 05:00 PM